BofA Securities recently downgraded PROCEPT BioRobotics from Buy to Neutral, citing slowing utilization growth and moderating system sales for its Aquablation technology amid tighter hospital capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback